Get the Stockscreener App
6.29
2.40%
-0.155
Candel Therapeutics Inc stock is traded at $6.29, with a volume of 592.00K.
It is down -2.40% in the last 24 hours and up +29.69% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$6.445
Open:
$6.3
24h Volume:
592.00K
Relative Volume:
0.63
Market Cap:
$315.15M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-3.7219
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
-10.40%
1M Performance:
+29.69%
6M Performance:
-11.03%
1Y Performance:
+13.54%
1-Day Range:
$6.1101
$6.34
1-Week Range:
$6.1101
$7.00
52-Week Range:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
6.29 | 322.91M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Is Candel Therapeutics Inc. stock overvalued or undervaluedMarket Forecast Review For 2025 - jammulinksnews.com
What makes Candel Therapeutics Inc. stock price move sharplyValue Investing Review From AI Tools - jammulinksnews.com
Is Candel Therapeutics Inc. a growth stock or a value stockFree Stock Data Feed Backed By Experts - jammulinksnews.com
How strong is Candel Therapeutics Inc. company’s balance sheetWealth Building Trend Scanner That Work - jammulinksnews.com
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Applying Wyckoff theory to Candel Therapeutics Inc. stockTop Gaining Picks With Entry Signals Identified - metal.it
Is it the right time to buy Candel Therapeutics Inc. stockExpert Picks Ideas For Smart Trading - jammulinksnews.com
What are the latest earnings results for Candel Therapeutics Inc.Beginner Investor Ideas For Smart Trading - jammulinksnews.com
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Why Candel Therapeutics Inc. stock attracts strong analyst attentionMomentum Based Equity Trading Plans Reviewed - beatles.ru
Candel Therapeutics to share company update at Canaccord Genuity Growth Conference - Proactive financial news
Candel Therapeutics CEO Dr. Tak to Share Cancer Immunotherapy Progress at Major Growth Conference - Stock Titan
Is Candel Therapeutics Inc. Stock a Good Fit for Conservative InvestorsAI Driven Buy Alert Trade Blueprint Released - metal.it
Published on: 2025-07-29 16:45:46 - metal.it
What machine learning models say about Candel Therapeutics Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
What catalysts could drive Candel Therapeutics Inc. stock higher in 2025Maximize your returns with expert insights - jammulinksnews.com
What are Candel Therapeutics Inc. company’s key revenue driversMaximize gains with data-driven stock picks - jammulinksnews.com
How does Candel Therapeutics Inc. generate profit in a changing economyNavigate market shifts with confidence - jammulinksnews.com
What is Candel Therapeutics Inc. company’s growth strategyExceptional market positioning - jammulinksnews.com
Will Candel Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsTechnical Breakout List - metal.it
What is the dividend policy of Candel Therapeutics Inc. stockAchieve consistent profits with proven methods - jammulinksnews.com
What are the technical indicators suggesting about Candel Therapeutics Inc.Massive profits - jammulinksnews.com
Candel Therapeutics Inc. Stock Analysis and ForecastFree Risk Assessment Services - PrintWeekIndia
What drives Candel Therapeutics Inc. stock priceFree Real-Time Stock Data - PrintWeekIndia
What analysts say about Candel Therapeutics Inc. stockMarket-leading profit generation - Autocar Professional
Is Candel Therapeutics Inc. a good long term investmentExplosive returns - PrintWeekIndia
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer - GlobeNewswire
Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment - citybuzz -
Can Candel Therapeutics Inc. stock recover from recent declineExceptional return forecasts - jammulinksnews.com
Small cap wrap: Blockmate Ventures, Candel Therapeutics, HIVE Digital, American Resources... - Proactive financial news
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409 - Proactive financial news
Revolutionary Pancreatic Cancer Treatment Shows 31.4-Month Survival, Secures Critical EU Designation - Stock Titan
(CADL) Trading Report - news.stocktradersdaily.com
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):